goralatide has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goodwin, JE; Kanasaki, K; Koya, D; Srivastava, SP | 1 |
| He, J; Ishigaki, Y; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nakamura, Y; Shi, S; Srivastava, SP | 1 |
2 other study(ies) available for goralatide and Diabetes Mellitus
| Article | Year |
|---|---|
Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus; Diabetic Nephropathies; Humans; Kidney; Male; Mice; Mice, Inbred C57BL; Oligopeptides | 2020 |
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.
Topics: Animals; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endothelial Cells; Fibroblast Growth Factor 1; Fibrosis; Humans; Interferon-gamma; Kidney; Mice; MicroRNAs; Microvessels; Models, Biological; Oligopeptides; Phosphorylation; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2016 |